ArticleRespiratory research2025
CXCR3-activating peptide inhibits pulmonary fibrosis in a bleomycin mouse model.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of CXCL10 in high-fat diet-induced skeletal muscle inflammation and atrophy.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Abnormal wound healing and dysregulated inflammation in the lung results in scarring and progressive fibrosis, which are hallmarks of Idiopathic Pulmonary Fibrosis (IPF) and post-COVID injury-related lung fibrosis. Chemokine signaling through the CXCR3 receptor and the CXCR3-activating chemokine interferon gamma-inducible protein of 10kD (CXCL10/IP10) have been implicated in the regulation of pulmonary fibrosis with full length CXCL10 preventing pulmonary fibrosis development in preclinical models. Therapeutic use of full length CXCL10p has been limited by protein instability in vivo. To address this challenge, we utilized a CXCL10 activating peptide (CXCL10p) and found that CXCL10p prevents lung fibrosis and inflammation in the bleomycin mouse model. Our findings suggest that CXCL10p may have improved therapeutic potential for the prevention progressive fibrotic lung diseases such as IPF and acute lung injury-related lung fibrosis. NEW & NOTEWORTHY : We show that the intratracheal treatment of CXCL10p in a bleomycin-induced lung injury mouse model of pulmonary fibrosis reduces lung fibrosis and inflammatory cell infiltration. This efficacy is dose- and timing-dependent. This study highlights the improved therapeutic potential of CXCL10p to regulate and reduce pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.